Myostatin gene inactivation prevents skeletal muscle wasting in cancer

Area of Science:

• Oncology
• Molecular Biology
• Physiology

Background:

• Cancer cachexia is a debilitating muscle-wasting syndrome linked to increased mortality in cancer patients.
• The precise mechanisms driving severe skeletal muscle loss in cachexia remain incompletely understood.
• Myostatin, a muscle protein, is investigated for its potential role in mediating cancer cachexia.

Purpose of the Study:

• To test the hypothesis that myostatin mediates muscle wasting in cancer cachexia.
• To investigate the impact of myostatin gene inactivation on muscle mass and tumor progression in mouse models of cancer.
• To elucidate the molecular pathways affected by myostatin in the context of cancer cachexia.

Main Methods:

• Utilized genetically modified mice with myostatin gene inactivation.
• Engrafted mice with Lewis lung carcinoma (LLC) cells and used Apc(Min) (/+) mice, a model for colorectal cancer and cachexia.
• Analyzed muscle protein degradation pathways, gene expression of atrophy and autophagy markers, tumor growth, and survival rates.

Main Results:

• Myostatin gene inactivation prevented severe skeletal muscle mass loss in both LLC and Apc(Min) (/+) mouse models.
• Loss of myostatin attenuated muscle fiber proteolytic pathways by inhibiting atrophy-related genes (MuRF1, MAFbx/Atrogin-1) and autophagy-related genes.
• Myostatin inhibition impeded LLC tumor growth and intestinal polyp development in Apc(Min) (/+) mice, significantly increasing survival.
• Gene expression analysis revealed reduced expression of genes involved in tumor metabolism, activin signaling, and apoptosis in the LLC model.

Conclusions:

• Myostatin is essential in the pathogenesis of cancer cachexia-induced muscle wasting.
• Myostatin inhibition demonstrates a dual effect, reducing muscle loss and impeding tumor growth.
• These findings establish a link between myostatin, cancer cachexia, and tumor progression, suggesting cancer's systemic nature.